Format

Send to

Choose Destination
J Histochem Cytochem. 2009 Jan;57(1):7-8. doi: 10.1369/jhc.2008.952820. Epub 2008 Oct 14.

Commercial antibodies: the good, bad, and really ugly.

Author information

1
Biomedicine Institute, University of Copenhagen, Biocenter, Ole Maaloes Vej 5, 2200 Copenhagen N, Denmark. john.couchman@bric.dk

Abstract

The range of antibodies available commercially grows ever larger. Perhaps as a consequence, quality control is not always what it could and should be. Investigators must be aware of potential pitfalls and take steps to assure themselves that the specificity of each antibody is as advertised. Additionally, companies should provide the necessary information about the antigen and antibody to investigators, including references, so that the appropriate controls can be included.

PMID:
18854593
PMCID:
PMC2605718
DOI:
10.1369/jhc.2008.952820
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center